Chimeric Animal Inflammation Prevention Technology

Publication ID: 24-11856927_0001_PTD

Published: October 27, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Chimeric Animal Inflammation Prevention Technology,” Published Technical Disclosure No. 24-11856927_0001_PTD, Published October 27, 2025, available at https://archive.pr1or.art/24-11856927_0001_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,927.

Background and Problem Solved

The original patent disclosed a method for obtaining an adult individual from a xenogeneic or allogeneic chimeric animal fetus individual, but it had limitations in addressing immune response and inflammation after birth. The present invention addresses these limitations by introducing a monitoring module, controlled release composition, and sensor-enabled device to prevent and treat inflammation in chimeric animals more effectively.

Novelty and Inventive Step

The present invention introduces novel elements, such as the monitoring module, controlled release composition, and sensor-enabled device, which are not present in the original patent. These elements provide an inventive step by enabling more efficient, safer, and targeted treatment of inflammation in chimeric animals.

Alternative Embodiments and Variations

Alternative embodiments of the invention could include varying the type of anti-inflammatory agent or immunosuppressive agent used, adjusting the controlled release mechanism, or integrating the system with other medical devices. Variations could also involve adapting the invention for use in different species or for treating different types of inflammation.

Potential Commercial Applications and Market

The invention has significant commercial potential in the fields of regenerative medicine, biotechnology, and veterinary care. It could be used to improve the health and well-being of chimeric animals, enabling the development of new therapies and treatments. The target market includes research institutions, biotech companies, and veterinary clinics.

CPC Classifications

Section	Class	Group
A	A01	A01K67/0271
A	A61	A61K31/573
A	A61	A61P37/06
A	A01	A01K2217/05
A	A01	A01K2217/075
A	A01	A01K2227/105
A	A01	A01K2267/035
C	C12	C12N15/09

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Veterinary biotechnology and immunological research, specifically focused on chimeric animal development, stem cell transplantation, and immunomodulatory interventions. Requires expertise in molecular biology, immunology, and veterinary medical techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in veterinary science or molecular biology, experienced in stem cell research, immunological monitoring, and chimeric animal treatment protocols. Familiar with immunosuppressive agents, inflammation detection methods, and controlled drug delivery systems

Obviousness Rationale

A person skilled in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about managing inflammation in chimeric animals. The proposed monitoring and controlled release systems directly address the source patent's fundamental goal of preventing post-birth immune responses. These technical modifications represent standard engineering approaches to enhancing the original patent's treatment methodology.

Obvious Combinations & Variations

Source Patent Element

Method for obtaining an adult individual from a chimeric animal fetus with no substantial inflammation

PTD Variation

Adding a monitoring module to detect immune response or inflammation in the epidermis

Obviousness Reasoning

Detecting inflammation is a predictable and routine diagnostic technique in veterinary immunology, representing a known method for implementing the source patent's treatment strategy

Source Patent Element

Administering anti-inflammatory or immunosuppressive agents before immune response occurrence

PTD Variation

Introducing a controlled release composition for targeted agent delivery

Obviousness Reasoning

Controlled drug delivery is a well-established pharmaceutical technique that would be obvious to modify the source patent's treatment approach for improved efficacy

Source Patent Element

Treatment of inflammation after birth in chimeric animals

PTD Variation

Integrating a sensor-enabled device for automated agent administration

Obviousness Reasoning

Automated medical monitoring and intervention systems are standard design choices in biomedical engineering, representing a predictable technological enhancement

Source Patent Element

Treating immunodeficient individuals with anti-inflammatory interventions

PTD Variation

Adding carrier molecules to enhance agent efficacy

Obviousness Reasoning

Pharmaceutical formulation optimization through carrier molecules is a routine technique for improving drug performance, representing a standard approach in drug development

Source Patent Element

Method for preventing post-birth immune responses in chimeric animals

PTD Variation

Expanding treatment protocols to different species and inflammation types

Obviousness Reasoning

Generalizing medical treatment protocols across species is a common scientific approach, representing an obvious extension of existing research methodologies

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11856927, the present technical disclosure demonstrates that the claimed variations in chimeric animal inflammation treatment would have been obvious to a person having ordinary skill in the art at the time of the invention. The proposed modifications represent predictable technological extensions utilizing standard techniques in veterinary immunology and pharmaceutical engineering, thus rendering potential patent claims obvious and unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,856,927
Title	Finding and treatment of inflammation after birth in chimeric animal
Assignee(s)	The University of Tokyo